AnaptysBio, Inc.
ANAB
$20.69
$0.3251.60%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.26M | 27.77M | 43.11M | 30.02M | 10.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.26M | 27.77M | 43.11M | 30.02M | 10.97M |
| Cost of Revenue | 37.82M | 41.18M | 42.59M | 42.21M | 42.00M |
| Gross Profit | -15.56M | -13.41M | 524.00K | -12.20M | -31.03M |
| SG&A Expenses | 10.61M | 14.13M | 10.19M | 10.56M | 9.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.43M | 55.31M | 52.78M | 52.77M | 51.29M |
| Operating Income | -26.17M | -27.54M | -9.67M | -22.76M | -40.32M |
| Income Before Tax | -38.59M | -39.29M | -21.79M | -32.85M | -46.65M |
| Income Tax Expenses | 39.00K | 44.00K | -6.00K | -- | 9.00K |
| Earnings from Continuing Operations | -38.63M | -39.33M | -21.78M | -32.85M | -46.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.63M | -39.33M | -21.78M | -32.85M | -46.66M |
| EBIT | -26.17M | -27.54M | -9.67M | -22.76M | -40.32M |
| EBITDA | -26.03M | -27.39M | -9.53M | -22.61M | -40.17M |
| EPS Basic | -1.34 | -1.28 | -0.72 | -1.14 | -1.71 |
| Normalized Basic EPS | -0.84 | -0.80 | -0.45 | -0.71 | -1.07 |
| EPS Diluted | -1.34 | -1.28 | -0.72 | -1.14 | -1.71 |
| Normalized Diluted EPS | -0.84 | -0.80 | -0.45 | -0.71 | -1.07 |
| Average Basic Shares Outstanding | 28.81M | 30.64M | 30.45M | 28.89M | 27.36M |
| Average Diluted Shares Outstanding | 28.81M | 30.64M | 30.45M | 28.89M | 27.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |